US Stock MarketDetailed Quotes
CASI CASI Pharmaceuticals
- 6.4500
- -0.2900-4.30%
Close Aug 23 16:00 ET
- 6.4500
- 0.00000.00%
Post 20:01 ET
99.72MMarket Cap-3177P/E (TTM)
6.7300High6.3900Low12.37KVolume6.7300Open6.7400Pre Close80.73KTurnover0.17%Turnover RatioLossP/E (Static)15.46MShares8.480052wk High11.06P/B47.33MFloat Cap1.900052wk Low--Dividend TTM7.34MShs Float11137.4899Historical High--Div YieldTTM5.05%Amplitude1.4500Historical Low6.5280Avg Price1Lot Size
CASI Pharmaceuticals Stock Forum
Sign in to post a comment
$Rivian Automotive (RIVN.US)$ this one is at least moving in the right direction, $CASI Pharmaceuticals (CASI.US)$
1
$CASI Pharmaceuticals (CASI.US)$ pump it up so u can short it
1
$CASI Pharmaceuticals (CASI.US)$ If you actually break 7? Will be looking for 7.93? NFA just thinking outloud
1
4
$CASI Pharmaceuticals (CASI.US)$ Break 6? will be looking for 7?
1
$CASI Pharmaceuticals (CASI.US)$ Look mom, no hands! Hehehe
1
$CASI Pharmaceuticals (CASI.US)$ Reuters
just
Board Got a Preliminary Non-Binding Proposal Letter Dated June 21, From Wei-Wu He, Chairman of Board and CEO of Company
CASI Pharmaceuticals Inc - Proposed Deal for Purchase Price of $40.0 Mln, Which Shall Include Assumption of up to $20.0 Mln of Indebtedness of Company
just
Board Got a Preliminary Non-Binding Proposal Letter Dated June 21, From Wei-Wu He, Chairman of Board and CEO of Company
CASI Pharmaceuticals Inc - Proposed Deal for Purchase Price of $40.0 Mln, Which Shall Include Assumption of up to $20.0 Mln of Indebtedness of Company
1
$CASI Pharmaceuticals (CASI.US)$
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company
CASI Pharmaceuticals plans to submit an Investigational New Drug (IND) application to the FDA by the end of 2024 for CID-103, a monoclonal antibody for treating antibody-mediated re...
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company
CASI Pharmaceuticals plans to submit an Investigational New Drug (IND) application to the FDA by the end of 2024 for CID-103, a monoclonal antibody for treating antibody-mediated re...
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
eternityawaits : Thanks been waiting for this!
Stock_Drift OP eternityawaits : I have $Innovative Eyewear (LUCY.US)$ and $Clearmind Medicine (CMND.US)$ waiting for some
action. 
eternityawaits : Nice!
let it squeeze : let her run![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
73282684 : you forgot ffie